Scripscan:Aarti Industries Ltd
cmp:52
Code:524208
Story:Aarti Industries is the flagship company of the Aarti group and is the market leader in benzene derivatives, with more than 50% market share. It has a diversified end-user profile manufacturing basic chemicals, speciality chemicals, agrochemicals and pharmaceuticals. It enjoys economies of scale from its large installed capacities for nitro- and chloro-benzene derivatives. What is turbo-driving the business is speciality chemicals.Manufacturing of APIs is done in Maharashtra (Tarapur and Dombivli) and Gujarat (Vapi, Sarigam and Jhagadia). The units are ISO/GMP certified. The API business at Tarapur managed by Aarti Healthcare sometimes back got the approval of United States Food and Drug Administration (US FDA). This will help to increase sales volume in the US market for various high-value APIs used in manufacturing cardio-vascular, anti-asthmatic, anti-cancer, anti-thalassemic, anti-hypertensive, anti-depressant drugs, etc. It has also backward-integrated its business so that it has access to intermediates of most of the APIs it manufactures. Aarti Healthcare has also been able to obtain a Certificate of Sustainability (COS) from the European authorities for one of its key high-growth anti-hypertensive API – Ramipril. The manufacturing units with backward integration and the logistic advantage of stocking points in the US, Europe and Japan are the strengths of the company.Finally, what is great about this company are its promoters. It is rare to find technocrats running Rs1,000 crore companies. Here is one. Chandrakant V Gogri, the chairman, is a chemical engineer from University Department of Chemical Technology (UDCT), Mumbai. He set up the Aarti group starting as a small unit three decades ago. His brother Rajendra Gogri, vice chairman, is a brilliant chemical engineer also from UDCT, Mumbai; he went on to do his master’s in chemical engineering from Iowa University of USA. Another director, Piramal Desai, is also a chemical engineer from UDCT, Mumbai.Seems worth adding on declines.
Subscribe to:
Post Comments (Atom)
Important Disclaimer&Privacy policy
This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: arunsharemarket@gmail.com
Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.
No comments:
Post a Comment